Mr Robert Vickery

Chief Financial Officer

Mr Vickery has over 25 years’ experience as a finance professional, with a particular focus on life sciences and innovation-based businesses. As Chief Financial Officer (CFO) of Viralytics, he was a key member of the team that accomplished the acquisition by Merck in June 2018 -- the largest ever transaction in the Australian biotech sector. While at Viralytics, Mr. Vickery managed several other major capital transactions and re-engineered key corporate functions, including IT, HR and insurance.

He has previously held senior roles with several biotech and innovation-based businesses, including as CFO and Company Secretary of ASX listed BioSignal Ltd. Early in his career he served in the Chartered Accounting profession before transitioning to a corporate role at Swire Group acting across a range of treasury, taxation and company secretarial functions. Mr. Vickery is an Associate of the Institute of Chartered Accountants and the Governance Institute of Australia.

No other team members found.

Join Our Mailing List

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect